Pylarify radiopharm
Active Awarded Last action
- Contract number
- 36C25025N0158
- Awardee
-
Progenics Pharmaceuticals Inc. UEI YLYKVRPCTCR3 Part of Lantheus Holdings, Inc.
- Awarding agency
-
Veterans Integrated Service Network 10
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $2,723,323
Award facts
- Contract value 51% obligated
-
- $2,723,322.56 Current, with exercised options
- $5,299,861.44 Potential, with all options
- Completion date 44% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- North Billerica, Billerica, MA 01862, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $1,455,488 | |
| Supplemental Agreement for work within scope | $259,828 | |
| Original award | $1,008,007 |
About this award
Progenics Pharmaceuticals Inc., operating as a division of Lantheus Medical Imaging, Inc., received a delivery order award on January 15, 2025, for $5.3 million to supply PYLARIFY radiopharmaceutical products through January 14, 2029. The contract, issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), supports the Department of Veterans Affairs' Veterans Integrated Service Network 10 and does not include a set-aside designation. PYLARIFY (piflufolastat F-18) is a radioactive diagnostic imaging agent used in positron emission tomography scans for detecting and localizing prostate cancer, providing critical diagnostic capabilities across VA medical centers and federal healthcare facilities. The manufacturing and fulfillment of this delivery order will be conducted at the company's facility in North Billerica, Massachusetts.
This delivery order represents a firm fixed-price procurement under an established federal supply schedule contract vehicle, enabling the VA to efficiently access radiopharmaceutical products essential for oncologic diagnostic imaging programs. Progenics Pharmaceuticals, as a specialized supplier of diagnostic imaging agents through its parent company Lantheus Holdings, Inc., maintains significant indefinite delivery contracts with the VA and Defense Health Agency valued up to $290 million, allowing federal healthcare providers to streamline procurement of critical nuclear medicine supplies. The award reflects ongoing federal reliance on the company's specialized radiopharmaceutical capabilities to support veterans' healthcare and medical imaging operations across the VA system.
Quick answers
Who was awarded contract 36C25025N0158?
36C25025N0158 was awarded to Progenics Pharmaceuticals Inc. by Veterans Integrated Service Network 10 (Veterans Health Administration) on January 15, 2025.
How much is contract 36C25025N0158 worth?
The government has obligated $2,723,323 on 36C25025N0158. Its potential value, with all options, is $5,299,861.
Is contract 36C25025N0158 an order under another contract?
Yes. 36C25025N0158 is a delivery order under 36F79719D0170, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C25025N0158 competed?
The extent of competition for 36C25025N0158 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award